Elvitegravir

Medical Advocates
Elvitegravir (GS-9137)

Main Page

New and Noteworthy
Elvitegravir/Tenofovir/Emtricitabine/Cobicistat
Journal Abstracts, Papers, and Commentaries
Conference Reports, Abstracts, and Posters
Cobicistat

Investigational ARVs

Main New/Noteworthy

Home Page

Last Update: April 20, 2018
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

New and Noteworthy

April 2018

A Trial of a Single Tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of HIV-2 Infection in a Resource-Limited Setting: 48 Week Results from Senegal, West Africa.
Ba S, Raugi DN, Smith RA, et al Clin Infect Dis. 2018 Apr 17

Investigational ARVs

Main New/Noteworthy

Home Page

Elvitegravir (GS-9137) Main Page